We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gilead Announces Phase I Data for an Investigational Compound for the Treatment of Chronic Hepatitis C

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gilead Announces Phase I Data for an Investigational Compound for the Treatment of Chronic Hepatitis C"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Gilead Sciences, Inc. has announced preliminary clinical data from an ongoing Phase I study of GS 9190, an investigational compound for the potential treatment of infection with the chronic hepatitis C virus (HCV).

These data were presented (Abstract # 49) by Ira Jacobson, MD, Chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Clinical Medicine, Weill Medical College of Cornell University, at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2007), currently taking place in Boston, Massachusetts (November 2-6).

GS 9190 is a non-nucleoside polymerase inhibitor that is being evaluated in a two-part Phase I study of treatment-naïve patients infected with HCV genotype 1.

In the first part of the study (Part A), a single dose of GS 9190 demonstrated encouraging pharmacokinetics and antiviral activity. The second, multiple dose part of the study (Part B) is designed to enroll 60 HCV infected patients in total, and assess the safety, tolerability, pharmacokinetics and antiviral activity of ascending doses of GS 9190, once or twice daily, for eight days. Results from Part A and initial results from the first two twice daily doses evaluated in Part B of the study were presented at the meeting.

“These Phase I data support continued evaluation of GS 9190 as a potential therapeutic option for HCV,” said Dr. Jacobson. “New, more convenient and better tolerated medicines for HCV are urgently needed, and we look forward to continuing our assessment of GS 9190 in this clinical program.”